|
VALIDD
Valsartan In Diastolic Dysfunction
Ongoing trial
 |
Author(s) |
Janardhanan R, Daley WL, Naqvi TZ, Mulvagh SL, Aurigemma G, Zile M, Arnold JMO, Artis E, Purkayastha D, Thomas JD, Solomon SD |
 |
Title(s) |
Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: Evolving the management of diastolic dysfunction in hypertension |
|
Reference(s) |
Am Heart J 2006;152:246–52 |
|
Disease |
Hypertension |
|
Purpose |
To explore whether antihypertensive therapy with valsartan in addition to standard therapy would improve diastolic function in patients with hypertension and evidence of diastolic dysfunction |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Aim 38 weeks |
|
Patients |
Aim 350 patients, aged ≥ 45 years, with BP > 140/90 mm Hg and ejection fraction > 50% |
|
Treatment regimen |
Valsartan, 160 mg/day, forced titrated to 320 mg/day, or placebo |
|
Concomitant therapy |
Standard antihypertensive therapy other than renin-angiotensin-aldosterone system blockers |
|
Results |
Not yet available |
|
|
|
